Bioharvest Financials
This page shows Bioharvest (BHST) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sales growth is improving unit economics, but the business still funds itself externally while cash reserves were rebuilt in FY2025.
The balance-sheet repair was externally funded, not earned: equity swung from-$14.9M to$25.4M across the period. Retained losses still deepened to-$107.6M , while financing supplied$30.2M of cash in the latest year, showing that solvency improved faster than the business's own cash generation.
Operating leverage is finally visible: revenue reached
Cash conversion still trails the income statement: operating cash flow was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Bioharvest's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bioharvest has an operating margin of -16.2%, meaning the company retains $-16 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -27.8% the prior year.
Bioharvest's revenue surged 37.0% year-over-year to $34.5M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
With a current ratio of 3.97, Bioharvest holds $3.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.
While Bioharvest generated -$7.2M in operating cash flow, capex of $2.4M consumed most of it, leaving -$9.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Bioharvest generates a -43.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -970.9% the prior year.
Bioharvest passes 3 of 9 financial strength tests. 1 of 2 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Bioharvest generates $0.65 in operating cash flow (-$7.2M OCF vs -$11.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Bioharvest generated $34.5M in revenue in fiscal year 2025. This represents an increase of 37.0% from the prior year.
Bioharvest's EBITDA was -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.1% from the prior year.
Bioharvest reported -$11.1M in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.
Cash & Balance Sheet
Bioharvest generated -$9.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 0.7% from the prior year.
Bioharvest held $23.0M in cash against $0 in long-term debt as of fiscal year 2025.
Bioharvest had 23M shares outstanding in fiscal year 2025. This represents an increase of 30.8% from the prior year.
Margins & Returns
Bioharvest's gross margin was 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 4.0 percentage points from the prior year.
Bioharvest's operating margin was -16.2% in fiscal year 2025, reflecting core business profitability. This is up 11.6 percentage points from the prior year.
Bioharvest's net profit margin was -32.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 19.0 percentage points from the prior year.
Bioharvest's ROE was -43.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 927.1 percentage points from the prior year.
Capital Allocation
Bioharvest invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 16.9% from the prior year.
BHST Income Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
BHST Balance Sheet
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Total Assets | N/A | N/A | N/A |
| Current Assets | $30.5M+288.2% | $7.9M-13.2% | $9.1M |
| Cash & Equivalents | $23.0M+863.4% | $2.4M-55.4% | $5.4M |
| Inventory | $4.6M+24.7% | $3.7M+48.2% | $2.5M |
| Accounts Receivable | $2.0M+77.5% | $1.1M+38.1% | $808K |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | N/A | N/A | N/A |
| Current Liabilities | $7.7M-46.1% | $14.3M-46.1% | $26.5M |
| Long-Term Debt | N/A | N/A | N/A |
| Total Equity | $25.4M+1813.4% | $1.3M+109.0% | -$14.9M |
| Retained Earnings | -$107.6M-11.5% | -$96.4M-15.5% | -$83.5M |
BHST Cash Flow Statement
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
BHST Financial Ratios
| Metric | Q4'25 | Q4'24 | Q4'23 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 3.97+3.4 | 0.55+0.2 | 0.34 |
| Debt-to-Equity | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Bioharvest's annual revenue?
Bioharvest (BHST) reported $34.5M in total revenue for fiscal year 2025. This represents a 37.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioharvest's revenue growing?
Bioharvest (BHST) revenue grew by 37% year-over-year, from $25.2M to $34.5M in fiscal year 2025.
Is Bioharvest profitable?
No, Bioharvest (BHST) reported a net income of -$11.1M in fiscal year 2025, with a net profit margin of -32.3%.
What is Bioharvest's EBITDA?
Bioharvest (BHST) had EBITDA of -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bioharvest's gross margin?
Bioharvest (BHST) had a gross margin of 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioharvest's operating margin?
Bioharvest (BHST) had an operating margin of -16.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bioharvest's net profit margin?
Bioharvest (BHST) had a net profit margin of -32.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bioharvest's return on equity (ROE)?
Bioharvest (BHST) has a return on equity of -43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bioharvest's free cash flow?
Bioharvest (BHST) generated -$9.6M in free cash flow during fiscal year 2025. This represents a -0.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioharvest's operating cash flow?
Bioharvest (BHST) generated -$7.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bioharvest's capital expenditures?
Bioharvest (BHST) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Bioharvest's current ratio?
Bioharvest (BHST) had a current ratio of 3.97 as of fiscal year 2025, which is generally considered healthy.
What is Bioharvest's cash runway?
Based on fiscal year 2025 data, Bioharvest (BHST) had $23.0M in cash against an annual operating cash burn of $7.2M. This gives an estimated cash runway of approximately 38 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bioharvest's Piotroski F-Score?
Bioharvest (BHST) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioharvest's earnings high quality?
Bioharvest (BHST) has an earnings quality ratio of 0.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioharvest?
Bioharvest (BHST) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.